SOLICITATION NOTICE
66 -- NanoString nCounter Prep Station
- Notice Date
- 9/10/2010
- Notice Type
- Presolicitation
- NAICS
- 334516
— Analytical Laboratory Instrument Manufacturing
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd., EPS Suite 600, Rockville, Maryland, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-100243-MM
- Archive Date
- 10/5/2010
- Point of Contact
- Melissa P Marino, Phone: 301-402-4509, Caren N Rasmussen, Phone: (301) 402-4509
- E-Mail Address
-
marinome@mail.nih.gov, cr214i@nih.gov
(marinome@mail.nih.gov, cr214i@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- Description The National Cancer Institute (NCI), Center for Cancer Research (CCR), Laboratory of Pathology plans to procure on a sole source basis the brand name NanoString nCounter Prep Station from NanoString Technologies, 530 Fairview Ave. North, Suite 2000, Seattle, WA 98109. This acquisition will be processed under FAR Part 12 - Acquisition for Commercial Items and will be made pursuant to the authority in FAR Part 13.106(b)(2) and 13.501-(a)(1) using simplified acquisition procedures for commercial acquisitions. The North American Industry Classification System code is 334516 and the business size standard is 500 employees. Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. Delivery Time: Approximately one week from date of award. The Molecular Diagnostics Laboratory of the Laboratory of Pathology performs molecular testing to assist in the diagnosis of a variety of cancers. The laboratory develops tests that assist in pathologic diagnosis, predict prognosis and identify potential targets for rational personalized therapies. It is currently the only CLIA and College of American Pathology approved clinical laboratory within the NCI certified for performing molecular oncology testing on materials from NIH patients. FAR Statute: 13.106-1 (b)(1) (b) Soliciting from a single source. (1) For purchases not exceeding the simplified acquisition threshold, contracting officers may solicit from one source if the contracting officer determines that the circumstances of the contract action deem only one source reasonably available (e.g., urgency, exclusive licensing agreements, or industrial mobilization). End of Clause No other requirement and/or type for supply or service will satisfy agency need. The NanoString nCounter system is a particularly versatile platform to interrogate 100s of DNA and RNA targets to establish diagnostic signatures for cancer. The system is also capable of assessing copy number DNA variants, and of identifying fusion transcripts in multiplexed reactions. Both capabilities provide additional opportunities for cancer test development. The nCounter assay is adaptable to paraffin extracted DNA and RNA, which makes it an especially attractive platform for a pathology laboratory, whose primary material storage is FFPE tissue. The Molecular Diagnostics Laboratory has established an informal agreement with the NCI core sequencing laboratory to have use of their current nCounter Analyzer. Therefore, the Molecular Diagnostics Laboratory has a need for only the prep station. Because of the proprietary nature of the nanoString technology, there is no other prep station that can interface with the nanoString nCounter Digital Analyzer, nor is there any other single system with the versatility of the nanoString platform (ability to quantify message and microRNA, assess gene copy number, and identify fusion transcripts), and which is also adaptable to partially degraded DNA from FFPE tissues, the major source of cancer tissue nucleic acid in all pathology laboratories. The salient unique features of the nCounter Prep Station that are required by the Molecular Diagnostics Laboratory of the Laboratory of Pathology are; •The Reporter Probes allows for direct measurement of individual RNA, micro RNA, and DNA molecules and provides a digital signal. •allows for the determination of DNA copy number variation •The probe sets have been developed to assess microRNA profiles •Can be utilized to assess the presence or absence of fusion transcripts and provide quantitative information at the same time. •multiplex up to 550 targets in a single reaction with sensitivity greater than that of microarrays. •The assay requires no enzymatic reactions, which removes the risk of potential enzymatic bias during detection. •The assay removes the requirement for sample purification and can measure RNA directly from cell lysates, tissue lysates, and purified RNA from PaxGene blood samples. •The Analysis System can detect target concentrations as low as 0.1fM (<1 copy per cell) •can perform with FFPE extracted nucleic acid 100 bp or greater •The Analysis System can quantitate endogenous gene concentrations through the use of the positive control curve included in the CodeSet. •The nCounter assay includes 10 positive controls in each CodeSet which generates a titration curve for quantitation of endogenous targets and to ensure system performance. •provides 10 negative controls to ensure effective background subtraction for more precise signal analysis •provides fully automated sample processing and data collection reducing the chance of user error. •The assay is simple, rapid, and would be adaptable to the clinical laboratory setting. •provides fully custom CodeSets in which two probes are designed for each nucleic acid target and must bind to detect a signal thus reducing the risk of possible cross hybridization false positive signal. This is not a solicitation for competitive quotations. However, if any interested party believes they can meet the above requirement, they may submit a statement of capabilities. All information furnished must be in writing and must contain sufficient detail to allow the NCI to determine if it can meet the above unique specifications described herein. An original and one copy of the capability statement must be received in the NCI Office of Acquisitions on or before 11:00 AM EST on September 20, 2010. No electronic capability statements will be accepted (i.e. email or fax). An original and one copy must be sent to the NCI Office of Acquisitions at the address stated above. All questions must be in writing and can be faxed (301) 402-4513 or emailed to Melissa Marino, Contract Specialist, at marinome@mail.nih.gov. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, contractors must have valid registration and certification in the Central Contractor Registration (CCR) www.ccr.gov and the Online Representations and Certifications Applications (ORCA), http://orca.bpn.gov. No collect calls will be accepted. Please reference solicitation number NCI-100243-MM on all correspondence.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/NCI-100243-MM/listing.html)
- Record
- SN02276699-W 20100912/100911000021-1c21b4521e65d6cf684dda489c3d9134 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |